Phase 2 Oesophageal Adenocarcinoma Clinical Trials
13 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–13 of 13 trials
Recruiting
Phase 2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Gastroesophageal Adenocarcinoma
AstraZeneca100 enrolled70 locationsNCT07069712
Recruiting
Phase 2
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Gastroesophageal Adenocarcinoma
Canadian Cancer Trials Group168 enrolled18 locationsNCT06043427
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled51 locationsNCT06469944
Recruiting
Phase 1Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled45 locationsNCT06445972
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Esophageal Squamous Cell CarcinomaAdvanced Unresectable Gastric AdenocarcinomaAdvanced Gastroesophageal Adenocarcinoma
BeOne Medicines30 enrolled1 locationNCT07554521
Recruiting
Phase 2
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Esophageal AdenocarcinomaGastric AdenocarcinomaPancreas Adenocarcinoma+6 more
Yale University54 enrolled1 locationNCT07282912
Recruiting
Phase 2
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
MetastasesHER2 + Gastric CancerFirst Line Therapy+2 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest80 enrolled20 locationsNCT07176312
Recruiting
Phase 1Phase 2
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Gastroesophageal AdenocarcinomaGastric Cancer Adenocarcinoma Metastatic
Bolt Biotherapeutics, Inc.122 enrolled16 locationsNCT06921837
Recruiting
Phase 2
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Metastatic Colorectal CancerMetastatic Gastroesophageal AdenocarcinomaDPD Deficiency
UNICANCER73 enrolled21 locationsNCT06245356
Recruiting
Phase 2
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
Gastroesophageal Adenocarcinoma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.204 enrolled39 locationsNCT06767800
Recruiting
Phase 2
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
Tumor MicroenvironmentOesophageal Adenocarcinoma
Amsterdam UMC, location VUmc14 enrolled2 locationsNCT06687876
Recruiting
Phase 2
Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
Gastric AdenocarcinomaGastroesophageal Adenocarcinoma
Jiangsu Cancer Institute & Hospital30 enrolled1 locationNCT06985602
Recruiting
Phase 1Phase 2
RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2
Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital42 enrolled3 locationsNCT05403242